English
简体中文
繁體中文
客服热线:400-1616-289
登录
注册
会议论文
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study
Wang, Xiaojia; Lee, Keun Seok; Zeng, Xiaohua; Sun, Tao; Im, Young-Hyuck; Li, Huiping; Wang, Kun; Li, Huiyan; Zhou, Ping; Bao, Yuanyuan; Jiang, Zefei
广东省人民医院; 南方医科大学; 中国医科大学; 重庆大学; 5
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
2023-6-1
6
阅读
引用
收藏
分享
相关
加载中…
文献加载失败,请重试
重试